Global Immunosuppressants Drugs Market is segmented By Drug Class (Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids, Other), By Indication (Organ Transplantation, Autoimmune Disorders, Non-Autoimmune Inflammatory Diseases), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Other), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Market Overview
The "Global Immunosuppressants Drugs Market" is predicted to reach at a high CAGR of 4.0% during the forecast period (2023-2030)
Immunosuppressant drugs are a class of drugs that suppress, or reduce, the strength of the body’s immune system. During organ transplantation, from a donor to a recipient, immune system of the recipient gets stimulated and thus, produces immune response like it does in response to other foreign material. This immune response causes serious damage to the transplanted or grafted organ. It is often called as rejection, which can be acute or chronic. This organ rejection is prohibited by using immunosuppressive drugs, which block the immune response and protect new organ and its function.
Source: DataM Intelligence Analysis (2020)
Market Dynamics
The global immunosuppressants drugs market growth is driven by innovations and advancements in organ transplantation procedures. The rise in volume of these procedures is driving the growth of the market in the forecast period.
The increasing prevalence of diabetes, is expected to drive the growth in the forecast period
An immunosuppressant is an agent that can suppress or prevent the immune response. Immunosuppressants drugs are used to prevent rejection of a transplanted organ and to treat autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, psoriasis/psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), inflammatory bowel disease, Addison’s disease, and graves' disease among others. Commonly used immunosuppressants drugs include tacrolimus, cyclosporine A, glucocorticoids, methotrexate, and rituximab.
According to the 2017 report of the International Diabetes Federation (IDF), approximately 425 million adults (20-79 years) were suffering from diabetes, and by 2045 this number may rise to 629 million, globally. Several government organizations and NGOs are working to increase awareness about the socioeconomic impact of autoimmunity through fostering and facilitating collaboration in the areas of education, public awareness, research, and patient services in an effective, ethical, and efficient manner. These factor will drive the growth of the market in the forecast period.
Increasing prevalence of autoimmune diseases,expected to drive the market growth
Increasing prevalence of autoimmune diseases, rising cases of organ failure and the requirement of organ transplantation and technological advancements in tissue engineering and organ transplantations are the key driving factors in the immunosuppressant drugs market. For instance, according to the U.S. National Kidney Association, 17,107 kidney transplants took place in the US. In addition, as per the U.S. Government Information on Organ Donation and Transplantation, 36,528 organ transplants were performed in 2018 in the country. For instance, as per the U.S. Government Information on Organ Donation and Transplantation, more than 113,000 number of individuals are on the national transplant waiting list as of July 2019. On the contrary, increase in use of tissue engineering for generation of implants provide growth opportunities for the market. In addition, rise in disposable income in developing economies and surge in awareness among individuals toward organ donation is anticipated to create lucrative opportunities for the market in the near future.
Dearth of availability of organ donors is likely to hinder the market growth
However, dearth of availability of organ donors and high cost of these drugs will hamper the growth of the market in the forecast period.
COVID-19 Impact Analysis
About 23.5 million Americans live with an autoimmune disease. Immunosuppression may increase the risk of developing COVID-19 or having a more severe cases. There are instances in which having an autoimmune disease increases vulnerability to COVID-19 complications, and other cases in which having a coronavirus infection may trigger autoimmune disease cases. This factor will hamper the market growth during the pendamic.
Segment Analysis
Calcineurin inhibitors segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Calcineurin Inhibitors segment holds a significant market share in the immunosuppressant drugs market due to its wide applications including utilization in organ transplant recipients and also for the treatment of autoimmune diseases. Calcineurin inhibitors are medicines that inhibit the action of calcineurin which is an enzyme that activates T-cells of the immune system. These inhibitors exert their effects by reducing interleukin-2 production and receptor expression, leading to a reduction in T-cell activation.
According to the U.S. Department of Health and Human Services and Health Resources and Services Administration, more than 113,000 people were in need of transplants as of 2019 and 36,528 transplants were performed in the year 2018. Increasing the prevalence of autoimmune diseases and the rapid rise in the number of organ transplants are the key driving factors in the calcineurin inhibitors segment. According to the National Institute of Environmental Health Sciences, autoimmune diseases affect more than 24 million people in the United States. In addition, eight million people have blood molecules, auto-antibodies that indicate a person’s chance of developing an autoimmune disease. These factors are driving the growth of the market in the forecast period.
The hospital pharmacy are expected to dominate the immunosuppressants drugs market during the forecast period
The hospital pharmacy held the largest share in the immunosuppressants drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is contributing to the growth of this segment.
Source: DataM Intelligence Analysis (2020)
Geographical Analysis
North America region holds the largest market share global immunosuppressants drugs market
North America is expected to hold a major market share in the global immunosuppressant drugs market due to the increasing prevalence of autoimmune diseases and the rapid rise in the number of organ transplants in this region. According to the Centers for Disease Control (CDC), in the year 2017, it was estimated that approximately 19 percent of men and 25 percent of women in the United States had doctor-diagnosed arthritis, in addition, doctor-diagnosed arthritis was prevalent in 16.4 percent of people who were underweight, while 27.7 percent of individuals who were obese. Furthermore, technological advancements in tissue engineering and organ transplantations, increasing healthcare spending coupled with increasing investments in the research and development and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent. Drug classes such as CETP inhibitors have been withdrawn or discontinued even in the later stages of trials due to adverse effects or failure to achieve satisfactory results. Risks associated with immunosuppressants pose a major challenge to their entry into the market.
Source: DataM Intelligence Analysis (2020)
Competitive Landscape
The immunosuppressants drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Astellas Pharma, Inc, Sanofi (Genzyme), Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer Inc, GlaxoSmithKline Plc, Allergan Plc, Accord Healthcare Ltd and Mylan Laboratories, Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the immunosuppressants drugs market globally.
Pfizer Inc
Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company sold its products in over 125 countries.
Product Portfolio: The Company’s portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.
Why Purchase the Report?
- Visualize the composition of the immunosuppressants drugs market segmentation by drug class, indication, distribution channel, and region highlighting the key commercial assets and players.
- Identify commercial opportunities in immunosuppressants drugs market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of immunosuppressants Drugs market - level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global immunosuppressants drugs market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
